Shuai Yue
Chongqing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8+ T cells.
Journal: Journal for immunotherapy of cancer
Published: February 23, 2026
Regulatory T cell-derived TGF-β signaling governs the differentiation and maintenance of tumor-infiltrating bystander CD8+ T cells.
Journal: Cell reports
Published: September 30, 2025
Oncolytic virotherapy mobilizes tumor-resident, granzyme B-producing bystander CD4+ T cells to inhibit systemic microbial infection.
Journal: Molecular therapy. Oncology
Published: August 20, 2025
Accessing Early Differentiation of Virus-Specific Follicular Helper CD4+ T Cell in Acute LCMV-Infected Mice.
Journal: Journal of visualized experiments : JoVE
Published: May 13, 2024
PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
Journal: Vaccine
Published: January 28, 2023
An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy.
Journal: Nature cancer
Published: January 17, 2023
Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 11, 2022
A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD.
Journal: Signal transduction and targeted therapy
Published: November 16, 2021
Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
Journal: Frontiers in immunology
Published: August 01, 2021
Last Updated: 09/26/2026